Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTY5VE)

• Drug Name: Lavoltidine Drug Info
• Synonyms: Loxtidine; AH-234844; GSK-1023911a; GSK-1040323b; Histamine H2 receptor antagonist (GERD), GlaxoSmithKline; Histamine H2 receptor antagonist (gastroesophageal reflux disorder), GlaxoSmithKline

Indication

Disease Entry	ICD 11	Status	REF
Gastroesophageal reflux disease	DA22.Z	Discontinued in Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 55473
  ChEBI ID: CHEBI:6550
  CAS Number: CAS 76956-02-0
  TTD Drug ID: DMTY5VE

Molecule-Related Drug Atlas

Drug(s) Targeting Histamine H2 receptor (H2R)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ranitidine	DM0GUSX	Peptic ulcer	DA61	Approved	[3]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[4]
Famotidine	DMRL3AB	Peptic ulcer	DA61	Approved	[4]
Nizatidine	DMGFV3Z	Acid-reflux disorder	DA22	Approved	[5]
Betazole	DMUFGAY	Gastric secretory disorder	DD90	Approved	[6]
Ebrotidine	DMV5KR3	Duodenal ulcer	DA63	Withdrawn from market	[7]
Pibutidine	DMXSTRM	Ulcerative colitis	DD71	Discontinued in Phase 3	[8]
Osutidine	DMN7TL8	Duodenal ulcer	DA63	Discontinued in Phase 3	[9]
KU-1257	DMZMFX6	Duodenal ulcer	DA63	Discontinued in Phase 3	[10]
IGN-2098	DMU4N1O	Duodenal ulcer	DA63	Discontinued in Phase 2	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Histamine H2 receptor (H2R)	TTQHJ1K	HRH2_HUMAN	Antagonist	[2]

References

• [1] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000092)
• [2] New and Future Drug Development for Gastroesophageal Reflux Disease. J Neurogastroenterol Motil. 2014 January; 20(1): 6-16.
• [3] Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
• [4] Histamine H1 and H2 receptor antagonists accelerate skin barrier repair and prevent epidermal hyperplasia induced by barrier disruption in a dry environment. J Invest Dermatol. 2001 Feb;116(2):261-5.
• [5] Does the use of nizatidine, as a pro-kinetic agent, improve gastric emptying in patients post-oesophagectomy J Gastrointest Surg. 2009 Mar;13(3):432-7.
• [6] Effect of nizatidine and cimetidine on betazole-stimulated gastric secretion of normal subjects: comparison of effects on acid, water, and pepsin. Am J Gastroenterol. 1988 Jan;83(1):32-6.
• [7] Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat. Arzneimittelforschung. 1997 Apr;47(4A):439-46.
• [8] Comparative pharmacology of epibatidine: a potent agonist for neuronal nicotinic acetylcholine receptors. Mol Pharmacol. 1995 Oct;48(4):774-82.
• [9] Effects of osutidine (T-593) and its enantiomers on gastric mucosal hemodynamics and mucosal integrity in anesthetized rats. Arzneimittelforschung. 2001 Jan;51(1):46-50.
• [10] Pharmacological profiles of the new histamine H2-receptor antagonist N-ethyl-N'-[3-[3-(piperidinomethyl)phenoxy] propyl] urea. Arzneimittelforschung. 1993 Feb;43(2):129-33.
• [11] Effects of IGN-2098, a new histamine H2-receptor antagonist, on gastric secretion and gastric and duodenal lesions induced in rats. Comparison with roxatidine. Nihon Yakurigaku Zasshi. 1992 Mar;99(3):167-80.